Abstract
Background Circulating omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) have been associated with various chronic diseases and mortality, but results are conflicting. Few studies examined the role of omega-6/omega-3 ratio in mortality.
Methods We investigated plasma omega-3 and omega-6 PUFAs and their ratio in relation to all-cause and cause-specific mortality in a large prospective cohort, the UK Biobank. Of 85,425 participants who had complete information on circulating PUFAs, 6,461 died during follow-up, including 2,794 from cancer and 1,668 from cardiovascular disease (CVD). Associations were estimated by multivariable Cox proportional hazards regression with adjustment for relevant risk factors.
Results Risk for all three mortality outcomes increased as the ratio of omega-6/omega-3 PUFAs increased (all Ptrend < 0.05). Comparing the highest to the lowest quintiles, individuals had 26% (95% CI, 15-38%) higher total mortality, 14% (95% CI, 0-31%) higher cancer mortality, and 31% (95% CI, 10-55%) higher CVD mortality. Moreover, omega-3 and omega-6 PUFAs in plasma were all inversely associated with all-cause, cancer, and CVD mortality, with omega-3 showing stronger effects.
Conclusions Using a population-based cohort in UK Biobank, our study revealed a strong association between the ratio of circulating omega-6/omega-3 PUFAs and the risk of all-cause, cancer, and CVD mortality.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institute of Health under the award number R35GM143060 (KY). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank received ethical approval from the research ethics committee (reference ID: 11/ NW/0382). Written informed consent was obtained from participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* YS and KY jointly supervised this project.
The previous version of the manuscript has been peer-reviewed by three reviewers for eLife. Based on the reviewers' comments, this version of the manuscript has been revised to remove some biomarkers (lipid classes and lipid particles) from the mediation analysis, to add details and clarification in methods, and to remove phrases that have causative implications.
Data Availability
The datasets analyzed during the current study are available from the UK Biobank through an application process (www.ukbiobank.ac.uk/).
Abbreviations
- 95%
- CI 95% confidence interval
- ANOVA
- Analysis of variance
- BMI
- Body mass index
- CRP
- C-creative protein
- CVD
- Cardiovascular disease
- DHA
- Docosahexaenoic acid
- DHA%
- Docosahexaenoic acid to total fatty acids percentage E2 Oestradiol
- EPA
- Eicosapentaenoic acid
- HR
- Hazard ratio
- LA
- Linoleic acid
- LA%
- Linoleic acid to total fatty acids percentage
- IGF-1
- Insulin-like growth factor 1
- Omega-3%
- Omega-3 fatty acids to total fatty acids percentage
- Omega-6%
- Omega-6 fatty acids to total fatty acids percentage
- PUFAs
- Polyunsaturated fatty acids
- Ref
- Reference
- SD
- Standard deviation
- SHBG
- Sex hormone binding globulin
- TTST
- Testosterone
